Ivacaftor Placebo

DRUG3 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Cystic Fibrosis

Phase 1

Phase 1, QT/QTC Interval Study in Healthy Subjects

CompletedNCT01910415

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2013-06-30End: 2014-03-31Updated: 2014-08-11

Phase 2

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

CompletedNCT01225211

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2010-10-31End: 2014-04-30Updated: 2015-10-05

Phase 3

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

CompletedNCT02347657

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2015-01-31End: 2017-01-20Updated: 2018-06-12

Related Papers

Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised.

2022-12-097 citations

S69 Retrospective analysis of physiological response patterns to tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR or heterozygous for f508del-CFTR and a residual function mutation

2018-11-162 citations

S68 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis homozygous for F508del-CFTR: patient-reported outcomes in a phase 3 randomized, controlled trial (EVOLVE)

2018-11-161 citations

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

2017-11-03559 citations

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for <i>F508del-CFTR</i>

Annals of the American Thoracic Society2017-02-0188 citations

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

New England Journal of Medicine2015-05-171603 citations

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

2014-06-24329 citations